KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Interest Expenses (2016 - 2026)

Pacific Biosciences Of California has reported Interest Expenses over the past 14 years, most recently at $1.7 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 36.89% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $7.0 million, down 48.15%, while the annual FY2025 figure was $7.0 million, 48.15% down from the prior year.
  • Interest Expenses for Q4 2025 was $1.7 million at Pacific Biosciences Of California, roughly flat from $1.7 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $3.7 million in Q1 2022 and troughed at $1.7 million in Q1 2025.
  • A 5-year average of $3.1 million and a median of $3.6 million in 2023 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: skyrocketed 570.04% in 2021 and later crashed 51.41% in 2025.
  • Year by year, Interest Expenses stood at $3.5 million in 2021, then rose by 4.86% to $3.6 million in 2022, then fell by 2.11% to $3.6 million in 2023, then fell by 22.79% to $2.8 million in 2024, then plummeted by 36.89% to $1.7 million in 2025.
  • Business Quant data shows Interest Expenses for PACB at $1.7 million in Q4 2025, $1.7 million in Q3 2025, and $1.7 million in Q2 2025.